Sponsors (4)
The bill expands access, training, and oversight for long‑acting injectable treatments for people with substance use disorders and serious mental illness, improving care but increasing federal costs, risking shifts away from other treatment options, and adding reporting burdens on agencies and providers.
People with substance use disorders and serious mental illness will gain clearer access to FDA‑approved long‑acting injectable medications and associated clinical services, including authorized lab testing and supportive counseling.
Clinicians and treatment programs will receive training on long‑acting injectable medication use, increasing provider capacity to deliver these treatments.
Congress and taxpayers will receive annual outcome reports on program implementation and clinician‑assessed outcomes, improving transparency and oversight within a year of enactment.
Taxpayers and state governments may face increased federal grant spending or need reallocation of existing funds to cover expanded services (injectables, testing, training).
People with substance use disorders and serious mental illness could experience a shift of resources toward long‑acting injectables at the expense of other treatment modalities some patients prefer or need.
HHS, state governments, and provider grantees will incur additional administrative burden to collect and report clinician‑assessed outcomes annually.
Based on analysis of 2 sections of legislative text.
Expands a federal grant program to explicitly cover FDA‑approved long‑acting injectable meds for SUD/SMI, lab testing, counseling, training, and requires annual outcome reports to Congress.
Amends the federal grant program in the Public Health Service Act that funds priority treatment for substance use disorders (SUD) and serious mental illness (SMI). The change explicitly allows grant funds to cover FDA‑approved long‑acting injectable (LAI) medications for SUD and SMI, related lab testing and supportive counseling, and training plus clinical services needed to use LAI medications. It also requires the Secretary to submit an annual report to Congress on program outcomes, beginning no later than one year after enactment, and applies to grants awarded after the law takes effect.
Introduced June 17, 2025 by Neal Patrick Dunn · Last progress June 17, 2025